Ticker

ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report)'s stock price passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $1.42 and traded as low as $0.1402. ProPhase Labs shares last traded at $0.1503, with a volume of 146,678 shares changing hands. Wall Street Analyst Weigh

$201.2 Million in Gross Claims with Expanding Settlement Activity Across Multiple Insurance Carriers Active Negotiations Support Estimated $50–$60 Million Net Recovery and Near-Term Cash Flow Potential UNIONDALE, NY, April 15, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and consumer products company, today reported its financial results…

Shares of ProPhase Labs, Inc. (NASDAQ: PRPH - Get Free Report) crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $1.86 and traded as low as $0.0720. ProPhase Labs shares last traded at $0.0751, with a volume of 37,941 shares traded. Analysts Set New Price Targets

Institutional Financing Interest Emerges for Receivables-Backed Financing Following Extensive Diligence UNIONDALE, NY, March 17, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today provided a business update regarding its Crown Medical Collections initiative and related strategic activities.

Each Initiative Has the Potential to Drive Significant Liquidity and Strengthen the Company's Balance Sheet UNIONDALE, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics and consumer products company, today announced that it has initiated a potential sale or strategic partnership process for BE-Smart, its clinically validated…